U.S. Markets closed

Equillium, Inc. (EQ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.03+0.07 (+1.17%)
At close: 4:00PM EDT

Equillium, Inc.

2223 Avenida De La Playa
Suite 105
La Jolla, CA 92037
United States
858 412 5302
http://equilliumbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees31

Key Executives

NameTitlePayExercisedYear Born
Mr. Daniel Mark BradburyExec. Chairman92.19kN/A1961
Mr. Bruce D. Steel C.F.A.Co-Founder, Pres, CEO & Director414.42kN/A1966
Dr. Stephen Connelly Ph.D.Chief Scientific Officer & Director516.61kN/A1982
Dr. Krishna R. PoluConsultant612kN/A1973
Mr. Jason A. KeyesChief Financial OfficerN/AN/A1971
Ms. Christine Zedelmayer M.B.A., P.M.P.Sr. VP & COON/AN/A1970
Mr. Michael MooreVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Matthew Ritter Ph.D.VP of Corp. Devel.N/AN/AN/A
Mr. Joel M. RothmanChief Devel. OfficerN/AN/A1969
Dr. Dolca Thomas M.D.Exec. VP of R&D and Chief Medical OfficerN/AN/A1971
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Corporate Governance

Equillium, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.